Cardio Diagnostics Holdings
CDIOCardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) is a biotechnology company based in the United States. The company's primary business focus is the development and commercialization of clinical tests for cardiovascular disease. Its approach integrates artificial intelligence with epigenetic and genetic analysis to create diagnostic and prognostic tools aimed at the prevention and management of cardiovascular conditions. The company's key offerings include the Epi+Gen CHD™ test, designed for assessing the risk of coronary heart disease, and the PrecisionCHD™ test, intended to aid in the diagnosis of obstructive coronary heart disease. These tests are developed to provide clinicians with information to guide patient care decisions. Cardio Diagnostics operates within the biotechnology and diagnostics sectors, with its technology and tests specifically targeting the field of cardiology. As a publicly traded entity, Cardio Diagnostics Holdings is subject to the reporting requirements of the U.S. Securities and Exchange Commission. The company's strategy involves pursuing regulatory clearances for its tests and establishing commercial partnerships to integrate its technology into healthcare systems for cardiovascular disease management.
CDIO · Stock Price
Historical price data
About
Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) is a biotechnology company based in the United States. The company's primary business focus is the development and commercialization of clinical tests for cardiovascular disease. Its approach integrates artificial intelligence with epigenetic and genetic analysis to create diagnostic and prognostic tools aimed at the prevention and management of cardiovascular conditions. The company's key offerings include the Epi+Gen CHD™ test, designed for assessing the risk of coronary heart disease, and the PrecisionCHD™ test, intended to aid in the diagnosis of obstructive coronary heart disease. These tests are developed to provide clinicians with information to guide patient care decisions. Cardio Diagnostics operates within the biotechnology and diagnostics sectors, with its technology and tests specifically targeting the field of cardiology. As a publicly traded entity, Cardio Diagnostics Holdings is subject to the reporting requirements of the U.S. Securities and Exchange Commission. The company's strategy involves pursuing regulatory clearances for its tests and establishing commercial partnerships to integrate its technology into healthcare systems for cardiovascular disease management.